Tau protein takes centre stage at Alzheimer’s summit

Tau is a protein that plays a structural role in healthy brain cells. In Alzheimer’s, it becomes chemically altered and clumps into so-called neurofibrillary tangles. These tangles accumulate inside neurons and are closely linked to cell death and worsening symptoms.

At the AAIC (Alzheimer’s Association International Conference), researchers gathered from around the world. According to the reporting, tau-targeting treatments and the blood-brain barrier are the central themes this year. The blood-brain barrier is the protective filter separating the brain from the bloodstream. It controls which substances enter and leave the brain, including potential drugs.

Why tau is now in the spotlight

Drugs that clear amyloid plaques have shown only modest clinical benefit in trials, even when they measurably reduced amyloid. This has renewed interest in tau as a therapeutic target. Tau accumulation correlates more strongly with cognitive decline than amyloid accumulation, making it potentially a more relevant intervention point.

Blood tests and early detection

A second theme at the conference is early detection via blood tests. New diagnostic blood markers, including tau variants, can detect Alzheimer’s-related changes decades before the first symptoms appear. This opens the door to preventive treatment, though it remains unclear in whom and at what point intervention would be beneficial.

From a longevity science perspective, tau and amyloid do not exist in isolation from broader ageing processes such as inflammation, vascular ageing, and declining cellular waste clearance (autophagy). How tau-targeting therapies relate to that broader ageing biology is an open question that conferences like AAIC are increasingly engaging with.

Read the original article